Key result
Hypertrophic cardiomyopathy is a heterogeneous disorder affecting 1 in 500 persons, characterized by asymmetric left ventricular hypertrophy and variable clinical outcomes.
Why the study?
Hypertrophic cardiomyopathy is a complex and heterogeneous disorder with variable natural history and clinical manifestations that require comprehensive understanding.
This overview highlights that HCM is a heterogeneous disorder affecting 1 in 500 people worldwide, with a clinical course ranging from asymptomatic to advanced heart failure or sudden death.
Hypertrophic cardiomyopathy (HCM) is a complex, heterogeneous disorder that affects approximately 1 in every 500 persons worldwide and about 750,000 Americans. It is characterized by left ventricular hypertrophy that is usually asymmetric, with enlarged myocytes in disarray, unexplained by loading conditions. Obstruction to left ventricular outflow occurs in approximately 60% of patients. The natural history and cardiac morphology of HCM are quite heterogeneous. Although most patients with HCM are asymptomatic or mildly symptomatic, a minority are disabled by dyspnea, angina, or syncope, develop advanced heart failure, or die suddenly.
No takes yet. Share an insight, caveat, or question.
Eugene Braunwald (2024) conducted a review in Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is a heterogeneous disorder affecting 1 in 500 persons, characterized by asymmetric left ventricular hypertrophy and variable clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: